Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Respiratory Syncytial Virus Infection

In brief

The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of clesrovimab in healthy pre-term and full-term infants. It is hypothesized that clesrovimab will reduce the incidence of respiratory syncytial virus (RSV)-associated medically attended lower respiratory infection (MALRI) from Days 1 through 150 postdose compared to placebo.

Key facts

Study ID
NCT04767373
Run by
Merck Sharp & Dohme LLC
People needed
3632
Starts
2021-04-07
Expected to finish
2024-07-09
Last updated by the study team
2026-02-11

Who can join

Age: any, up to 1. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.